Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Angiogenesis inhibitors

angiogenesis inhibitor and inhibitor technology, applied in the field of angiogenesis inhibitors, can solve the problems of unstable, toxic, difficult to employ various materials, etc., and achieve the effect of removing or reducing normal but undesired tissue in a patien

Inactive Publication Date: 2013-04-25
THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019]In yet another embodiment, the invention provides a method, use, device, or formulation for eliminating or reducing normal but undesired tissue in a patient.

Problems solved by technology

However, many materials which appear promising in vitro have proven to be relatively ineffective when applied in vivo.
Furthermore, various of such materials have been found to be unstable, toxic, or otherwise difficult to employ.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Angiogenesis inhibitors
  • Angiogenesis inhibitors
  • Angiogenesis inhibitors

Examples

Experimental program
Comparison scheme
Effect test

examples

Materials and Methods

[0241]Library construction.

[0242]32,000 FDA drug approvals obtained by Freedom of Information Act requests were condensed to 3,400 unique drug formulations. Drugs were purchased from Sigma, Spectrum Chemicals, MP Biomedicals, The Johns Hopkins Hospital pharmacy, Biomol, and Tocris. 10 mM stock solutions were made using DMSO, water, or ethanol as solvents. Drugs were arrayed in 96-well plates and screened at a final concentration of 10 μM. Cells were incubated with drug for 36 h and proliferation was measured by pulsing with 1 μCi [3H]-thymidine for 8 h followed by absorption onto glass filters and scintillation counting.

[0243]Statistical Analysis.

[0244]IC50 measurements were carried out in triplicate, and analyzed using four parameter logarithmic analysis. Values are presented + / − the standard error of the mean. P-values were calculated using the Student's T-test.

[0245]Semi-Quantitative RT-PCR.

[0246]RNA from subconfluent proliferating HUVEC (1×106) cells was pre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
half lifeaaaaaaaaaa
particle sizeaaaaaaaaaa
concentrationsaaaaaaaaaa
Login to View More

Abstract

Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. Ser. No. 11 / 630,596, filed Dec. 17, 2007, which is a 35 U.S.C. §371 National Stage Application of PCT Application No. PCT / US2005 / 023015, filed Jun. 27, 2005, which claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Application Ser. No. 60 / 583,076, filed Jun. 25, 2004. The disclosure of each of the prior applications is considered part of, and is incorporated by reference in, the disclosure of this application.GRANT INFORMATION[0002]This work described herein was supported by a grant from the National Cancer Institute (NCI) (Grant No. CA078743). Therefore, the U.S. Government may have certain rights in the invention.BACKGROUND OF THE INVENTION[0003]Angiogenesis may be defined as the development of a blood supply to a given area of tissue. The development of a blood supply may be part of normal embryonic development, represent the revascularization of a wound bed, or involve the stimula...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/58A61K45/06A61F9/00
CPCA61K31/00A61K31/365A61K31/4164A61K31/4196A61K31/47A61F9/0017A61K31/58A61K31/7072A61K38/50A61F9/0008A61K45/06A61K31/496A61P17/00A61P17/02A61P17/06A61P17/10A61P17/12A61P19/02A61P27/02A61P29/00A61P31/00A61P31/04A61P31/10A61P31/12A61P31/22A61P35/00A61P35/02Y02A50/30
Inventor LIU, JUNCHONG, CURTISSULLIVAN, DAVID J.
Owner THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com